NCT05111249 - A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions

Early Manifest Huntington Disease

Interventions

DRUG

Branaplam

messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.

DRUG

Placebo

Matching placebo oral solution once weekly

Trial Locations (12)

Novartis Investigative Site, Szeged

Novartis Investigative Site, Madrid

Novartis Investigative Site, Bochum

Novartis Investigative Site, Münster

Novartis Investigative Site, Angers

Novartis Investigative Site, Lille

Novartis Investigative Site, Ulm

Novartis Investigative Site, Créteil

Novartis Investigative Site, Montreal

Novartis Investigative Site, Budapest

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Barcelona